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SUMMARY
The aim of the European Sero-Epidemiology Network is to establish comparability of the
serological surveillance of vaccine-preventable diseases in Europe. The designated reference
laboratory (RL) for measles, mumps, rubella (MMR) prepared and tested a panel of 151 sera by
the reference enzyme immunoassay (rEIA). Laboratories in 21 countries tested the panel for
antibodies against MMR using their usual assay (a total of 16 diﬀerent EIAs) and the results were
plotted against the reference results in order to obtain equations for the standardization of
national serum surveys. The RL also tested the panel by the plaque neutralization test (PNT).
Large diﬀerences in qualitative results were found compared to the RL. Well-ﬁtting
standardization equations with R2o0.8 were obtained for almost all laboratories through
regression of the quantitative results against those of the RL. When compared to PNT, the rEIA
had a sensitivity of 95.3%, 92.8% and 100% and a speciﬁcity of 100%, 87.1% and 92.8% for
measles, mumps and rubella, respectively. The need for standardization was highlighted by
substantial inter-country diﬀerences. Standardization was successful and the selected
standardization equations allowed the conversion of local serological results into common units
and enabled direct comparison of seroprevalence data of the participating countries.
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INTRODUCTION
Surveillance of population immunity is an important
component in the evaluation of intervention pro-
grammes as it allows an assessment of the past and the
current risk of infectious diseases in a population.
This is particularly relevant for vaccine-preventable
diseases for which alternative vaccination strategies
may be employed. When vaccination coverage is sub-
optimal, susceptible individuals accumulate, which
can lead to future outbreaks. Serological surveys
allow the early identiﬁcation of susceptible cohorts,
allowing targeted interventions, e.g. catch-up cam-
paigns to be undertaken [1–4]. Serological surveys can
also be used to evaluate the impact of campaigns and
ascertain elimination status [5–7]. The aim of the
European Sero-Epidemiology Network (ESEN2)
project was to coordinate and harmonize the sero-
logical surveillance of immunity to a variety of vac-
cine-preventable infections in Europe in order to
improve vaccination policies and strategies. ESEN2
was started in 2001 and is the continuation of the
successful original project ESEN [8] by extending
the coordination of serological surveillance to more
diseases (as well as diphtheria, pertussis, measles,
mumps, and rubella also included are hepatitis A
and B, and varicella zoster) and to more countries
(22 instead of the original eight).
For epidemiological purposes the enzyme im-
munoassay (EIA) is the widely used method to detect
antibodies to measles, mumps, and rubella in serum.
However variations in both the sensitivity and speci-
ﬁcity of several commercial EIAs have been reported
as well as inter-laboratory variability when the same
assay is used [9–11]. Standardization of assays is a
pre-condition to ensure direct comparability of any
seroepidemiology results obtained during the project.
In this paper the results of standardizing the measles,
mumps and rubella (MMR) assays are presented.
MATERIALS AND METHODS
Standardization procedure
The method used for standardization is given in detail
by Kafatos et al. [12] and was similar to that used for
the ﬁrst ESEN project [11]. In brief the aim was to
construct a reference panel containing enough sera
(y150) to represent the antibody values with high,
low, equivocal and negative levels for MMR. The
panels were distributed to and tested by a laboratory
in each of the participating countries using their
established antibody detection method. The same
method had to be used for testing the national serum
bank which was collected by each country according
to the project guidelines [8].
After the ﬁrst round of testing of the reference
panel the quantitative results were plotted against
those of the reference laboratory (RL). For the pur-
pose of the analysis, results above the upper detection
limit were doubled and those below the lower detec-
tion limit were halved [11]. Outliers were identiﬁed
and a linear, quadratic or sigmoid regression line
ﬁtted and the proportion of the variance explained by
diﬀerent regression lines was calculated (R2).
For each country agreement of the non-
standardized qualitative results with those of the RL
was calculated. Agreement within negatives is deﬁned
as the percentage of the RL negative samples (e.g.
n=28 for measles antibodies) each laboratory found
negative, agreement within positives is the percentage
of the RL positive or equivocal samples (e.g. n=123
for measles antibodies) found positive or equivocal
in each laboratory, and overall agreement is the per-
centage of the 151 samples where each laboratory
gave the same qualitative result as the RL.
The reference panel was tested for a second time
during testing of the national serum bank. The results
from this second round were compared with the re-
sults of the ﬁrst test to identify potential assay drift
[12]. The choice of the standardization equation was
based on the results that were obtained during testing
the national serum bank [12]. To successfully obtain
standardized results the chosen regression line should
ﬁt the data well around the equivocal range and
should ideally explain at least 80% of the variance
(R2 >0.8). The coordinating centre to whom all data
were sent for calculation and evaluation was the
Health Protection Agency Centre for Infections, UK.
Countries that tested their national serum bank
more than one year prior to the start of the project
required a diﬀerent approach for standardization
called back-standardization [12]. A panel of about
150 sera was selected randomly from the national
serum bank of those countries using back-standardiz-
ation after stratifying the samples by result (positive,
equivocal, negative). This national panel was tested
by the RL as well as by the laboratory in the country
concerned. The results were processed as described
above.
Overall 22 countries took part in the standardiz-
ation of the measles, mumps, and rubella results
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(Table A1, available in the online Appendix).
Four countries (Finland, Israel, Spain, Sweden)
had already completed the testing of their national
serum bank more than 1 year prior to back-
standardization being performed (Finland only for
mumps). Luxembourg and the Czech Republic had
also already tested their national serum banks, how-
ever, as this wasf1 year ago and they were still using
the same assays back-standardization was not re-
quired. Nevertheless these countries retested a panel
of the national serum bank to conﬁrm that no major
changes of the results had occurred. These countries
only tested the reference panel once as did Greece and
The Netherlands who participated only for the pur-
pose of method comparison of all three antigens or of
selected antigens (Australia for mumps and rubella,
Finland for measles and rubella, Spain for rubella).
Preparation of the reference panel
The preparation and distribution of the reference
panel was undertaken by the reference laboratory,
the National Reference Centre on Measles, Mumps,
Rubella (NRC MMR) at the Robert Koch Institute,
Berlin, Germany. The panel consisted of 151 samples.
The majority of samples (111) were collected in 2001
by the PHLS in Preston from students in the North
West of England. Between 4.2 ml and 9.5 ml of sera
were obtained from each student, most of whom had
immunity against measles, mumps and rubella ac-
quired either through natural infection or by vacci-
nation. As an inadequate number of negative sera
were collected, 16 samples were created from 42 chil-
dren (pooling 2–3 sera) whose sera were negative
for measles, mumps and/or rubella antibodies. The
remaining 24 samples of the panel were prepared
using the 2nd International Standard for anti-measles
serum, human (66/202), the 2nd British Standard
for anti-rubella serum, human (67/182) and the 2nd
Working Standard for anti-mumps serum (3/2000)
and seven dilutions of these standards. The latter
standard was prepared in the RL using a blood
donation of a patient with acute mumps and it pro-
vided 600 U after calibration against the 1st mumps
Working Standard [11].
The sera of the reference panel were tested by the
RL four times in 2001 using commercial EIAs
(Enzygnost, Dade Behring, Germany), which provide
quantitative antibody values for measles and rubella
in IU/ml and for mumps in titres. The mean antibody
values were calculated and the samples classiﬁed as
negative, equivocal, and positive (Table A2, available
online). Aliquots of 0.2 ml of all 151 sera and stan-
dard dilutions were prepared, stored at x25 xC until
shipment to the laboratories in the participating
countries.
Serological methods
The RL used commercial EIAs to detect virus-speciﬁc
IgG against measles, mumps and rubella (Enzygnost)
in the samples of the reference panel. The tests were
performed according to the manufacturer’s instruc-
tions, allowing quantiﬁcation by measuring the op-
tical density (OD) of a single serum dilution (1:231) of
the antigen and control antigen also. The diﬀerence
of these ODs (DOD) corrected by an internal control
were used to evaluate the qualitative result accord-
ing to the following cut-oﬀ values : OD <0.100=
negative, OD 0.100–0.200=equivocal, OD>0.200=
positive. Quantitative speciﬁc antibody values (SAV)
were calculated with the equation: log10 SAV=
a*DOD
b, where a and b were constants speciﬁc for
the reagent’s batch [13]. The SAV according to the
deﬁned cut-oﬀ were considered as shown in Table A2
(online).
The laboratories of the 22 participating countries
used diﬀerent commercial as well as in-house EIAs
providing quantitative values which started at diﬀer-
ent detection limits (Table A1, online). Nearly half of
the participants used the same kit as the RL (ten for
measles and mumps antibodies, nine for rubella).
The reference panel was also tested using the plaque
neutralization test (PNT) to check the sensitivity and
speciﬁcity of the reference EIAs (Enzygnost). The
PNT to detect measles and rubella antibodies was
performed at the RL, using a standard procedure [14].
Serum samples were diluted beginning at 1:2, in-
cubated with virus dilutions of 20–30 plaque-forming
units (p.f.u.) (measles virus strain L16, rubella virus
strain RA27/3) before the inoculation of cell mono-
layers. The neutralizing antibody titre was the re-
ciprocal of the highest serum dilution which caused
o50% reduction of plaque number. Titres of o1:2
were positive and corresponded after calibration
against the above-mentioned International Standards
too0.04¡0.02 IU/ml measles antibodies ando4¡2
IU/ml rubella antibodies respectively. The PNT to
detect mumps antibodies was performed at the lab-
oratory of Berna Biotech Ltd, Berne, Switzerland.
Dilutions of sera were incubated with mumps virus
(wild virus strain ‘9337-Altstetten’, 15–50 p.f.u.).
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Monolayer of Vero cells, grown on Lab TekII culture
plates were incubated with the serum-virus mixture
for 5 days after adding an overlay of carboxy-
methylcellulose. Plaques were detected by immuno-
ﬂuorescence technique. Neutralizing antibody titre
was deﬁned as the reciprocal of the highest serum
dilution which neutralized at least 50% of viral
plaques in comparison to the control and titres of
o1:2 were positive. The anti-mumps PNT was de-
veloped and validated using in-house positive and
negative sera according to international guidelines
[15, 16].
The qualitative results of testing the reference panel
by EIA (Dade Behring) were compared with those
obtained by PNT. For calculating the sensitivity and
speciﬁcity of the EIA the equivocal EIA results were
included as positives.
RESULTS
First and second round of panel testing
After the ﬁrst testing of the MMR reference panel two
participants (Cyprus, Malta) had to change the EIA
kit for detection of measles and mumps antibodies
as the chosen assay did not work adequately (R2
values were not acceptable). It transpired after the
ﬁrst testing and plotting of the results of all partici-
pants against those of the RL that an extension of the
detection limits could improve the regression lines
and the R2 values. Therefore values below the rec-
ommended negative cut-oﬀ were calculated using the
measured OD values [12] (Table A1, online).
Most of the participants tested the MMR panel
twice. The assay drift between the ﬁrst and second test
was mostly minor and the correlation between the
results of the two test runs was suﬃciently good
(R2>0.8, detailed results available at the ESEN2
website [17]). Primarily, the results of the second test
of the reference panel were chosen because this was
performed during the testing of the national serum
bank. The identiﬁcation of outliers performed as
previously described [12] revealed overall a small
number of f5 (3.5%) per participant among the
measles, mumps and rubella results. No sample
number was found to be a systematic outlier.
Results of standardization
The agreements for overall positive (including
equivocal) and negative results obtained before
standardization by all participants in relation to the
reference results are given in Tables 1–3 for measles,
mumps and rubella, respectively. The chosen optimal
standardization equation with the corresponding R2
value and eﬀect of standardization illustrated by
the equivocal ranges in local units before and after
standardization is shown for the measles, mumps, and
rubella results in Tables 1–3, respectively. Plots of all
the quantitative results against the RL along with the
ﬁtted regression lines can be found at the ESEN2
website [17].
Measles results
Comparison of qualitative results. A high overall
agreement (>95%) was shown by most of the
laboratories (8/10) using the same kit as the RL (Dade
Behring) as well as the laboratories (7/11) that used
diﬀerent EIAs than the RL. An especially low overall
agreement was observed in those laboratories using
the Hycor kit [Belgium (56%), Bulgaria (84%)] which
showed a strong underestimation of positive results
(47–81%, Table 1).
Quantitative comparisons. Mostly quadratic re-
gression equations (19/21) were selected. The R2
values were generally well above 0.90 and a R2 of
o0.95 was more often obtained (6/10) in laboratories
using the same EIA as the RL than in laboratories
using other EIAs (4/11). The R2 value was <0.90 in
only two laboratories (Israel 0.79, Sweden 0.89). Both
countries performed back-standardization (Table 1).
Examples for plotting the local results of three par-
ticipants (Belgium, Romania and Sweden) against
those of the RL are given in Figure A1 (top row)
(see online Appendix).
Mumps results
Comparison of qualitative results. A high overall
agreement (>95%) was noted for ﬁve out of 11
laboratories using the same kit as the RL and one
showed only 78% agreement (Israel, which per-
formed back-standardization). For ﬁve out of 10
laboratories using other EIAs than the RL an overall
agreement of >95% was also noted, but it was
below 90% in three laboratories (Cyprus, Bulgaria,
Malta). The low overall agreement was mostly caused
by a considerable underestimation of negatives
(45–76%), but low agreement of positive results was
also observed (Cyprus 87%, Malta 79%) (Table 2).
Quantitative comparisons. In total an R2 value of
o0.95 was obtained in only three out of 21
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Table 1. Comparison of qualitative measles results of all participants with those of the reference laboratory testing the MMR reference panel by diﬀerent
EIAs, the chosen optimal regression equation and the equivocal ranges before and after standardization for each participant
Agreement of qualitative results in %
Quantitative results
Optimal standardization equation Equivocal ranges in local units
Used kit
DB
Country
Germany (RL)
Negatives
(n=28)
Positives$
(n=123)
Overall
(n=151)
Equation of
standardization line· R2
Before std.
0.15–0.35 IU/ml
After std.
0.15–0.35 IU/ml
DB Australia 71 100 95 y=0.93x+0.15 0.91 0.15–0.30 0.24–0.53
DB England & Wales 100 98 99 y=0.11x2+1.06xx0.31 0.97 0.15–0.35 0.08–0.17
DB Finland* 100 98 99 y=0.09x2+1.02xx0.16 0.99 0.15–0.34 0.12–0.25
DB Greece* 100 97 97 y=0.13x2+1.14xx0.12 0.94 0.15–0.35 0.11–0.24
DB Israel# 77 98 95 y=0.07x2+0.87x0.10 0.79 0.15–0.35 0.17–0.33
DB Lithuania 93 97 96 y=0.12x2+1.05xx0.29 0.96 0.15–0.35 0.08–0.18
DB Luxembourg 92 99 98 y=0.06x2+1.00xx0.06 0.95 0.15–0.34 0.14–0.31
DB Romania 96 100 99 y=0.10x2+1.01xx0.18 0.97 0.15–0.30 0.11–0.24
DB Slovenia 96 99 99 y=0.04x2+1.08xx0.02 0.98 0.17–0.31 0.13–0.31
DB Spain# 100 100 100 y=x0.06x2+1.01x+0.20 0.94 0.15–0.35 0.21–0.53
Biotech Eire 100 97 98 y=x0.11x2+0.39x+0.27 0.98 0.90–1.10 0.75–1.17
ER Cyprus 100 90 92 y=0.15x2+1.00xx0.20 0.93 0.25 0.12–0.24
HC Belgium 100 47 56 y=0.06x2+0.74+1.15 0.94 27–40 3.81–6.68
HC Bulgaria 100 81 84 y=0.03x2+0.63x+1.50 0.94 27–40 10.03–16.56
HU Latvia 100 95 96 y=0.07x2+0.66xx0.06 0.93 0.40–0.60 0.28–0.45
In-house The Netherlands* 100 97 97 y=0.18x2+1.08xx0.29 0.94 0.20 0.09–0.18
In-house Sweden# 89 93 93 y=0.32x2+1.02xx0.41 0.89 0.15–0.35 0.09–0.16
SK Czech Republic 100 100 100 y=x0.25x2+0.97x+3.10 0.96 200–400 135–4.03
VR Hungary 90 100 98 y=0.15x2+0.93xx0.01 0.95 0.15–0.20 0.21–0.40
VR Malta 93 99 98 y=0.10x2+0.86xx0.20 0.92 0.15–0.20 0.14–0.27
VT Slovakia 97 98 98 y=0.51x+1.42 0.97 9.0–11.0 10–15
DB, Dade Behring ; ER, Euroimmun; HC, Hycor ; HU, Human; SK, Seiken; VR, VirionSerion ; VT, Virotech; n, samples of the reference panel ; std., standardization; RL,
reference laboratory.
* Countries took part for quality assurance only.
# Countries performed back standardization.
$ Positive including equivocal sera.
· y is the log10 local result ; x is the log10 of reference result (Germany).
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Table 2. Comparison of qualitative mumps results of all participants with those of the reference laboratory testing the MMR reference panel by diﬀerent
EIAs, the chosen optimal regression equation and the equivocal ranges before and after standardization for each participant
Agreement of qualitative results in %
Quantitative results
Optimal standardization equation Equivocal ranges in local units
Used kit
DB
Country
Germany (RL)
Negatives
(n=42)
Positives$
(n=109)
Overall
(n=151)
Equation of
standardization line· R2
Before std.
230–500
After std.
230–500
DB Australia* 100 99 99 y=0.94x+0.09 0.96 230–500 204–424
DB England & Wales 89 99 97 y=0.93x+0.21 0.94 230–500 255–525
DB Finland# 98 93 95 y=0.30x2x0.70x+2.39 0.91 230–500 257–485
DB Greece* 98 91 93 y=0.08x2+0.38x+0.93 0.82 230–500 188–345
DB Israel# 45 99 78 y=0.14x2+0.14x+1.48 0.83 231–543 390–755
DB Lithuania 95 100 99 y=0.04x2+0.70x+0.39 0.98 150 185–372
DB Luxembourg 83 100 96 y=x0.06x2+1.12x+0.16 0.92 231–525 295–557
DB Romania 83 100 96 y=0.06x2+0.68x+0.46 0.94 150–300 252–540
DB Slovenia 83 100 95 y=1.04x+0.03 0.94 190–370 306–687
DB Spain# 76 100 95 y=0.12x2+0.30x+1.36 0.85 230–500 547–1106
DB Sweden# 65 100 89 y=0.25x2x0.38x+2.06 0.89 230–500 361–717
Captia Eire 97 97 97 y=x0.09x2+1.05xx2.01 0.94 0.9–1.1 0.9–1.5
ER Cyprus 92 87 89 y=0.86xx1.04 0.87 20 10–19
HC Belgium 90 97 95 y=0.33x2x0.42x+0.63 0.89 27–40 30–79
HC Bulgaria 54 100 88 y=x0.05x2+0.94x+0.12 0.91 27–40 115–196
HU Latvia 89 100 97 y=0.93xx0.67 0.95 39–46 34–69
In-house The Netherlands* 92 99 97 y=x0.06x2+1.04xx0.46 0.92 40 46–81
SK Czech Republic 74 98 92 y=x0.16x2+1.66xx0.50 0.82 200–400 337–653
VR Hungary 95 99 98 y=0.74x+0.19 0.94 70–100 87–154
VR Malta 98 79 84 y=0.18x2x0.17x+1.30 0.9 150–200 80–142
VT Slovakia 93 97 96 y=0.58xx0.44 0.91 9–11 9–13
DB, Dade Behring ; ER, Euroimmun; HC, Hycor ; HU, Human; SK, Seiken; VR, VirionSerion; VT, Virotech ; n, samples of the reference panel, std., standardization; RL,
reference laboratory.
* Countries took part for quality assurance only.
# Countries performed back standardization.
$ Positive including equivocal sera.
· y is the log10 local result ; x is the log10 of reference result (Germany).
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laboratories and the R2 was<0.90 in seven out of 21
laboratories ; among these were three of the four par-
ticipants that had performed back-standardization.
No diﬀerence was observed between laboratories
using the same EIA or using diﬀerent EIAs than the
RL (Table 2). The regression equations are linear
(7/21) as well as quadratic (14/21). Figure A1
(middle row) (see online) shows three examples for
plotting the local results of participants (Bulgaria,
Hungary and Spain) against those of the RL.
Rubella results
Comparison of qualitative results. The overall agree-
ment was very good (mostly 99%) in laboratories
using the same kit as the RL (Dade Behring) with
one exception (Israel, which had performed back-
standardization). Laboratories using the EIA kit
from DiaSorin showed a lower overall agreement of
93–95% with a systematic underestimation of posi-
tive results. In two of the eight remaining laboratories
a low overall agreement of 90% and 88% was noted,
mainly caused by underestimation of negative results
(Table 3).
Quantitative comparisons. The regression equations
were quadratic (13/21), linear (5/21) as well as sigmoid
(2). All laboratories using the EIA kit of Dade
Behring or DiaSorin showed R2 values of o0.90,
most of them (9/13) had a R2o0.95. In laboratories
using other EIA kits or in-house EIA the R2 ranged
from 0.81 to 0.98 and only few laboratories (3/8)
showed R2 values of o0.95. Figure A1 (bottom
row) (see online) shows three examples for plotting
the local results of participants (Lithuania, The
Netherlands, Slovakia) against those of the RL.
Dilutions of the 2nd British Standard for anti-
rubella serum included in the reference panel were
blindly tested by the participating laboratories. The
levels of anti-rubella virus-IgG in IU/ml detected in
the dilutions diﬀered widely from the expected
values. In the four dilutions containing 40, 20, 15 and
10 IU/ml the following minimal and maximal values
were reported: 22–70; 13–39; 5–28; and 5–20 IU/ml,
respectively. The measured SAV in the dilutions of
the standards for anti-measles and anti-mumps serum
diﬀered in a similar wide range (data not shown).
Evaluation of the MMR reference panel by PNT
For measles antibodies the EIA showed, in compari-
son to PNT, a sensitivity of 95.3% (122/128 positives)
and a speciﬁcity of 100% (23/23 negatives). The EIA
for mumps antibodies had in comparison to the PNT
a lower sensitivity of 92.8% (103/111), and the speci-
ﬁcity was only 87.1% (34/39) because three equivocal
and two positive sera were negative by PNT. The
sensitivity of the EIA for rubella antibodies was
100% (105/105), but the speciﬁcity was only 93.7%
(30/32) since two sera with equivocal EIA results were
negative by PNT.
DISCUSSION
The aim of the ESEN2 project was to provide com-
parable seroprevalence data for vaccine-preventable
diseases, and in particular measles, mumps and
rubella, across the participating countries. The EIA is
the suitable method for investigating large numbers
of sera since kits are commercially available and the
assay can be automatically performed.
However, as we and other investigators have dem-
onstrated, there are diﬀerences in the reported results
[9–11]. In our study, we noticed a wide range of
overall agreement (56–100%) of the qualitative re-
sults of the RL compared with those of the labora-
tories using other kits than Dade Behring, either
due to a strong underestimation of positive results
(47%, measles antibodies by the Hycor kit ; Hycor
Biomedical GmbH, Kassel, Germany) or of negative
results (58%, rubella antibodies by the Platelia kit ;
Bio-Rad S.A., Sanoﬁ Diagnostics Pasteur, Marnes-la-
Coquette, France). Even if laboratories used the same
kit as the RL cases of underestimation were found
among positive results ; but more often among the
negative results (mainly mumps results).
All the rubella kits and most of the measles kits
employed by the diﬀerent laboratories provided the
antibody values in IU. The high variation of the
antibody values for the diﬀerent standard dilutions in
the panel blindly tested by the participants indicate
that the results are not always reliable despite the fact
that they are expressed in IU/ml. The wide variety of
the EIA results obtained by the diﬀerent kits in the
diﬀerent laboratories underlines the necessity of a
standardization of the results of antibody testing
to achieve an inter-country comparability of the sero-
prevalence data.
Results of standardization
For all participants and all antigens satisfactory stan-
dardization equations were obtained that explained
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Table 3. Comparison of qualitative rubella results of all participants with those of the reference laboratory testing the MMR reference panel by diﬀerent
EIAs, the chosen optimal regression equation and the equivocal ranges before and after standardization for each participant
Agreement of qualitative results in %
Quantitative results
Optimal standardization equation Equivocal ranges in local units
Used kit
DB
Country
Germany (RL)
Negatives
(n=35)
Positives$
(n=116)
Overall
(n=151)
Equation of
standardization line· R2
Before std.
4–7 IU/ml
After std.
4–7 IU/ml
DB Australia* 94 99 98 y=1.15xx0.19 0.97 4–7 3–6
DB Finland* 97 100 99 y=0.14x2+0.55x+0.27 0.99 4–6.5 4–7
DB Greece* 100 96 97 y=0.10x2+0.73x+0.13 0.92 5–10 4–7
DB Israel# 80 100 94 y=0.87x+0.19 0.91 4–7 5–8
DB Lithuania 97 100 99 y=0.09x2+0.89xx0.09 0.98 4–7 3–5
DB Luxembourg 97 100 99 y=0.05x2+0.75x+0.23 0.97 4–6 5–8
DB Romania 97 100 99 y=0.10x2+0.74x+0.19 0.95 4–7 5–8
DB Slovenia 94 100 99 y=0.05x2+0.93x+0.10 0.98 4–7 5–8
DB Spain* 91 100 98 y=0.98x+0.13 0.97 4–7 5–9
DO Belgium 100 91 93 y=x0.09x2+1.31xx0.34 0.96 9–11 3–5
DO Czech Republic 100 93 95 y=0.09x2+0.74x+0.07 0.90 9–11 4–6
DO Hungary 100 92 94 y=x0.06+(2.58/(1+exp(2.96x2.40x))) 0.95 10–15 3–5
DO Slovakia 100 94 95 y=0.68+(1.68/(1+exp(4.80x3.61x))) 0.97 9–11 6–8
Abbott Malta 65 96 90 y=0.25x2+0.25x+0.53 0.86 5–10 6–8
Biokit Eire 100 99 99 y=0.87x+0.31 0.98 10–15 7–11
In-house The Netherlands* 91 98 97 y=0.81x+0.57 0.93 10 11–18
In-house Sweden# 100 97 97 y=0.11x2+0.56x+0.42 0.91 7.4–10 6–9
Microgen England & Wales 100 99 99 y=0.12x2+0.83x+0.14 0.95 4–7 5–8
PL Bulgaria 87 97 95 y=0.81x+0.63 0.88 10–15 13–21
PL Latvia 58 96 88 y=0.20x2+0.40x+0.71 0.81 10–15 11–16
Radim Cyprus 100 91 93 y=x0.46x2+2.67x-1.41 0.98 8–10 1–3
DB, Dade Behring ; DO, DiaSorin ; PL, Platelia ; n, samples of the reference panel ; std., standardization ; RL, reference laboratory.
* Countries took part for quality assurance only.
# Countries performed back standardization.
$ Positive including equivocal sera.
· y is the log10 local result ; x is the log10 of reference result (Germany).
7
9
4
A
.
T
isch
er
a
n
d
o
th
ers
https:/w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S0950268807008266
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of B
asel Library, on 11 Jul 2017 at 14:44:59, subject to the C
am
bridge C
ore term
s of use, available at
most of the variability (R2=0.80) with only one
exception (Tables 1–3). R2 values of <0.90 were
reported more often with standardization of mumps
results (7) than either measles (3) or rubella (3). This
reﬂects a higher variability of the mumps results as
already noted on the comparison of qualitative results
and indicates that the mumps antigen used in EIA kits
is very diﬀerent. A further cause may be the relatively
high percentage of equivocal and low positive
mumps antibody values in the sera of the panel,
another cause might be the genetic variability of
the diﬀerent mumps virus strains used in the EIAs
[18, 19]. Participants that used back-standardization
obtained mostly lower R2 values and also the
lowest R2 value (0.79, measles results of Israel) was
achieved by a participant who performed back-
standardization.
The comparison of equivocal ranges before and
after standardization demonstrates the changes en-
tailed after using the chosen regression equation. In
case of underestimation of positive results by any kit
the standardization resulted in lowering the original
equivocal range (e.g. the measles results of Belgium,
Bulgaria, Sweden) or in case of overestimation of
positive results standardization resulted in raising the
original equivocal range (e.g. mumps results of Israel,
Bulgaria). When the standardization equation is
applied on the results of the national serum bank the
seroprevalence data of the respective country will
change as illustrated by the following example.
A slight underestimation of positive measles results
(90%) was obtained by the Euroimmun EIA kit
(Euroimmun AG, Lu¨beck, Germany) in the Cyprus
laboratory (Table 1). The equivocal range decreased
by standardization. Therefore, the proportion of sero-
positive samples increased in the corresponding sero-
proﬁle (Fig. A2, online). Applying this procedure to
the seroprevalence data will ensure direct compar-
ability with those of other countries participating in
the inter-country comparison.
Evaluation of EIA results by PNT
The sera of the MMR reference panel were also
measured by the PNT for measles, mumps and rubella
antibodies to evaluate the sensitivity and speciﬁcity of
the EIA (Dade Behring) used by the RL. The PNT is a
very sensitive and functional method whereby the
antibodies neutralize the capacity of the virus to infect
cells [20]. Neutralizing antibodies are commonly
assumed to correlate with protection.
Measles antibodies
Other authors reported a slightly lower sensitivity
(92%, 88%) for the EIA from Dade Behring in
comparison to PNT because they did not consider the
equivocal sera [9, 10]. The equivocal values of the
reference EIA range from 0.15 to 0.35 IU/ml; all
equivocal sera of the panel were positive by PNT with
0.17–1.2 IU/ml. Therefore, it seems justiﬁed to add
the proportion of equivocal to the positive sera in
the scope of the ESEN2 project. The antibody level
which gives protection against infection or illness
is still under debate. Individuals with a measles anti-
body level of >0.20 IU/ml measured by PNT were
protected against typical measles [9, 21]. On the other
hand persons with PNT titres<0.05 IU/ml developed
only an asymptomatic infection [22].
Mumps antibodies
Several studies compared diﬀerent types of EIAs
and neutralization tests besides other methods for
mumps antibody detection and found a good agree-
ment [23, 24] as well as discrepancies [25, 26]. The
antibody values measured by PNT and an in-house
EIA did not correlate well as was also found in our
comparison. In vaccine trials a higher sensitivity
for EIA was found [27, 28], but there is evidence
that antibodies to mumps cross-react with other
paramyxoviruses, such as human parainﬂuenza,
particularly in EIA [29, 30]. Further, it was shown
that the mumps virus strain used in the neutralization
test had a strong eﬀect on the measured titres [26].
The assessment of immunity to mumps virus remains
problematical due to the lack of an International
Standard for human mumps serum and the dis-
crepancies in detecting mumps antibodies.
Rubella antibodies
The equivocal values of the reference EIA range
from 4 to 7 IU/ml and sera with >7 IU/ml are con-
sidered to be positive. Since the speciﬁcity of the
EIA compared to PNT was not 100% it is proposed
that the proportion of sera with equivocal values
should not be added to positive sera in the scope of
ESEN2. However, the protective titre is assumed to
be 10 IU/ml (for the United States [31]) or 15 IU/ml
[32, 33]. These values are of special interest for
the evaluation of the percentage of women of child-
bearing age with a suﬃcient rubella antibody level in
the range of seroprevalence studies.
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The results of this paper demonstrate the import-
ance of the standardization procedure to control
inter-assay and laboratory diﬀerences. By applying
the selected standardization equations we will be able
to undertake international comparisons of measles,
mumps and rubella seroprevalence data in Europe
and provide a sound knowledge base with which to
evaluate MMR vaccine policies in Europe. These
results will be presented in further papers published
within the scope of ESEN2. The presented method
and results are also valuable and useful for countries
which did not participate in the project.
APPENDIX. Members of ESEN2
Belgium: S. Broodhaers, P. van Damme, L. D. Cock,
H. Theeten, R. Vranckx. Bulgaria : N. Gatcheva, Z.
Mihneva, V. Voynova. Cyprus: C. Hadjianastassiou,
M. Zarvou. Czech Republic : B. Kriz, V. Nemecek.
England & Wales : N. Andrews, N. Gay, W. J.
Edmunds, L. Hesketh, G. Kafatos, E. Miller, P.
Morgan-Capner, A. Nardone, R. Pebody. Finland: I.
Davidkin, R. M. O¨lander, M. Valle. Germany: W.
Hellenbrand, W. Thierfelder, A. Tischer. Greece: C.
Anastassopoulou, A. Hatzakis, A. Tsakris. Hungary:
K. Bartha, A. Csohan, I. Karacs, I. Lontai, M.
Melles, Zs. Molnar, Zs. Pauliny. Ireland: M. Carton,
L. Jones, D. O’Flanagan. Israel : Y. Aboudy, D.
Cohen, M. Green, E. Marva, Z. Smetana. Italy: G.
Gabutti, A. Giammanco, G. Icardi, C. Rota, S.
Salmaso, C. von Hunolstein. Latvia : J. Bebris, A.
Duks, J. Perevoscikovs, I. Rezebergs, I. Selga, I.
Velicko. Lithuania: V. Baksenas, A. Griskevicius, J.
Suracienne. Luxembourg: J. Mossong, F. Schneider.
Malta: A. Amato-Gauci, C. Barbara. The Nether-
lands :G. Berbers, H. deMelker, Romania:V. Alexan-
drescu, D. Butur, E. Lupulescu, A. Pistol, R. Viorica.
Slovakia: B. Cˇerna´kova´, J. Lancˇova´, E. Ma´derova´, I.
Rovny´, M. Slacˇikova´. Slovenia: A. Kraigher, K.
Prosenc. Spain: F. de Ory, J. M. Echevarria, M. V.
Martı´nez de Arago´n. Sweden: R. M. Carlsson, K.
Johansen, E. Reizenstein.
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